Samsung Biologics (KRX:207940), a contract development and manufacturing organisation (CDMO) based in South Korea, announced on Tuesday that it has entered into a collaboration agreement with pharmaceutical company Eli Lilly and Company (NYSE:LLY) to establish a Lilly Gateway Labs (LGL) site in Korea.
The new Gateway Labs site will serve as a hub to support early-stage and emerging biotechnology companies as they advance scientific research toward development and manufacturing. Samsung Biologics said that the facility will feature flexibly designed laboratory space and research infrastructure, collaborative space, and operational support, with capacity for up to 30 companies jointly selected by Lilly and Samsung.
Under the agreement, Samsung Biologics will develop and operate the new facility, with Lilly Gateway Labs providing customised scientific engagement to support resident biotech companies and catalyse collaboration across the Korea life sciences sector.
Located within Samsung Biologics' Bio Campus II site, the 125,000 sq ft facility is expected to be completed in July 2027.
Target ALS awards two-year research grant to AcuraStem for advancing therapeutics targeting SYF2
Ascletis reports Phase II weight‑loss results for ASC30 depot formulation
NS Pharma and NCNP report 4.5-year brogidirsen data for DMD treatment
Biofrontera reports Phase 2b data for Ameluz photodynamic therapy in acne vulgaris treatment
Koselugo approved in Canada for adults with NF1 and inoperable plexiform neurofibromas
Bristol Myers Squibb reports positive Phase 3 results for oral mezigdomide in multiple myeloma
Pfizer reports positive Phase 2 results for trispecific antibody in atopic dermatitis
Agilent to acquire Biocare Medical for USD950m to expand pathology portfolio
Ipsen withdraws tazverik across all markets following safety concerns in lymphoma trial